SABA Overuse INSIGHT Clinician Survey

1. What percentage of your asthma patients are prescribed Short-acting beta2-agonist (SABA) inhalers as monotherapy (eg: salbutamol or levosalbutamol)?

<10%

10–30%

31–50%

51%-75%

>75%

2. What percentage of your asthma patients are prescribed Short-acting beta2-agonist (SABA) inhalers along with Inhaled corticosteroid (ICS) or ICS-long-acting beta2-agonists (ICS-LABA)?

<10%

10–30%

31–50%

51%-75%

>75%

3. What percentage of your asthma patients are on Maintenance and Reliever Therapy (MART) with ICS-formoterol?

<10%

10–30%

31–50%

51%-75%

>75%

4. In your opinion, what percentage of your asthma patients overuse SABA (>3 canisters/ year)?

<10%

10–30%

31–50%

51%-75%

>75%

5. What in your opinion is the biggest concern with SABA overuse? (Choose all that apply)

A. Increased risk of exacerbations

B. Masking poor asthma control

C. Patient dependency

D. Increased risk of mortality

E. Increased risk of drug-related adverse events like tachycardia

F. Increased risk of receptor saturation and tachyphylaxis

G. No major concern

6. In your experience, what percentage of patients achieve good asthma control with SABA-based treatment (ICS-SABA, ICS-LABA with PRN SABA or SABA monotherapy)?

<20%

20–40%

41–60%

61-75%

>75%

7. In your experience, what percentage achieve good control with MART?

<20%

20–40%

41–60%

61-75%

>75%

8. What is your main barrier to prescribing MART? (Choose all that apply)

Cost of medication

Patient resistance

Lack of familiarity

Limited availability

No barrier

9. What do you think is the most effective way to reduce SABA overuse (Choose all that apply)?

Patient education

Stricter prescribing protocols

Wider adoption of MART

Digital monitoring tools

Controlling over the counter (OTC) availability of SABA inhalers

Others (Please specify)

10. How closely does your asthma management align with GINA recommendations (e.g., avoiding SABA monotherapy, using ICS-based reliever therapy)?

Fully aligned – I follow GINA guidance for all asthma patients without exceptions

Mostly aligned – I follow GINA for most patients, but occasionally deviate based on clinical judgment

Partially aligned – I apply GINA selectively for certain patient profiles or severity levels

Rarely aligned – I generally use my own protocols and only refer to GINA in complex cases

Not aligned – I do not follow GINA recommendations in my practice

11. Are you aware that SABA inhaler overuse contributes to environmental impact?

A. Yes, and I actively consider this in my prescribing decisions

B. Yes, but it does not influence my prescribing decisions

C. No, I was not aware

D. Unsure

12. Which therapy do you believe has a lower environmental impact in terms of carbon footprint?

A. ICS-formoterol as MART reduces up to 42% CO₂ emissions compared to SABA-containing regimens

B. SABA inhalers lower up to 42% CO₂ emissions compared to MART

C. Both therapies have similar environmental impact as both contain propellants

D. MART likely has lower impact, but I am not fully sure of the extent

E. Unsure / Need more information

INSIGHT Survey

A survey among physicians to gain INSIGHTs into treatment choices, perceptions and barriers in asthma management

DEMOGRAPHIC INFORMATION

(Please choose only one option unless mentioned otherwise for the below questions)